We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.04 | 0.04% | 97.13 | 97.82 | 96.92 | 97.08 | 1,630,756 | 01:00:00 |
From May 2019 to May 2024
Novartis said the annualized cost of Zolgensma will be $425,000 a year for five years. "Novartis' Zolgensma Approved for Sale in U.S. to Treat SMA in Infants at $425,000 a Year," at 1308 ET, misstakenly called the company Novaratis in the last paragraph.
(END) Dow Jones Newswires
May 24, 2019 18:36 ET (22:36 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
